Join
Live feed
·
PRReleasevia Quantisnow
Seelos Therapeutics Inc. logo

Seelos Therapeutics announces the signing of a Material Transfer Agreement with U.S. Army Medical Materiel Development Activity (USAMMDA) to evaluate SLS-002 for treatment of PTSD

ByQuantisnow·Wall Street's wire, on your screen.
SEEL· Seelos Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SEEL (Seelos Therapeutics Inc.) and more on Quantisnow.